ANI Pharmaceuticals Launches Generic Carbamazepine Capsules In $65 Million U.S. Market

ANI Pharmaceuticals has announced the launch of Carbamazepine Extended-Release Capsules in strengths of 100 mg, 200 mg, and 300 mg. The product is a generic version of Carbatrol, expanding ANI’s portfolio in the central nervous system (CNS) therapeutics segment.

Carbamazepine extended-release capsules are commonly used in the management of neurological conditions such as epilepsy and certain mood disorders. By introducing a generic alternative, ANI aims to provide a more affordable treatment option while maintaining the same safety, efficacy, and quality standards as the reference listed drug.

"Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. “The launch of Carbamazepine Extended-Release Capsules, another limited competition product, highlights our continued commitment to improving patient access to essential medicines while maintaining the highest standards of quality and compliance.”

According to IQVIA data for the 12 months ending February 2026, the U.S. market for carbamazepine extended-release capsules generated approximately $65 million in annual sales, highlighting a steady commercial opportunity for the company within the generics space.

ANI Pharmaceuticals continues to focus on sustainable growth through its diversified business model, which includes rare disease, generics, and branded products. The company’s strategy emphasizes innovation, operational excellence, and U.S.-based manufacturing to deliver high-quality therapies across multiple therapeutic areas.

Also Read :

ANI Pharmaceuticals Launches Generic Isosorbide Mononitrate Tablets For Angina Treatment, Following FDA Approval